VeriLuce Therapeutics is an early-stage company currently focusing on the computational design and development of small molecule(s) targeting and antagonizing chemokine receptors within the tumor micro-environment. The intent is to slow-down/block angiogenesis and metastasis of cancer. VeriLuce’s compound(s) differentiates from other chemokine receptor antagonists by each targeting a specific ‘dual-receptors-combination’ not yet targeted by other chemokine antagonists. This differentiation could potentially provide a novel and effective ‘tumor micro-environment modulation’ to help fight cancer.

VeriLuce Therapeutics  logo



Event details

Date: September 14 - 16, 2020

Event contact

Patricia Cosgrove
Area Director
USA: Life Sciences


16 in total